Vanguard Capital Management
FATE icon

Vanguard Capital Management’s Fate Therapeutics FATE Stock Holding History

Vanguard Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
4,445,536
+253,473
+6% +$469K ﹤0.01% 2712
2026
Q1 		$5.03M Buy
+4,192,063
New +$5.1M ﹤0.01% 3057

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management's FATE Position: Q2 2026 in Review

Vanguard Capital Management increased its Fate Therapeutics (FATE) stake by 6% in Q2 2026, buying an estimated $469K and bringing the position to 4,445,536 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #2712.

Vanguard Capital Management first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 152 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Vanguard Capital Management held 4,445,536 shares of Fate Therapeutics worth $12M as of Q2 2026.
  • Vanguard Capital Management bought 253,473 Fate Therapeutics shares in Q2 2026, an estimated $469K.
  • Fate Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2712 holding.
  • Vanguard Capital Management first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 152 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.